

Disclosure of Amendments to Code of Business Conduct & Ethics

On December 22, 2025, the Board of Directors (the “Board”) of Rhythm Pharmaceuticals, Inc. (the “Company”) approved an amended and restated Code of Business Conduct and Ethics (the “Code”) which, among other things, addresses honest and ethical conduct; full, fair, accurate, timely, and understandable disclosure in SEC filings; compliance with applicable governmental laws, rules and regulations; prompt, internal reporting of violations; and accountability for adherence to the Code. The updated Code maintains the essential principles and standards contained in the prior Code. Other changes to the policy include changes of a technical, administrative and non-substantive nature.

The foregoing summary is qualified in its entirety by reference to the full text of the Code. The amendments to the Code do not result in any waiver, explicit or implicit, from any provision of the Code as in effect prior to the Board’s actions to amend the Code.